Indica Labs, a provider of computational pathology software, and AI technology firm Paige have formed a non-exclusive partnership aimed at integrating Paige’s diagnostic AI models into Indica’s anatomic pathology workflow management software, HALO AP.
This will include Paige’s pan-cancer AI application developed using Paige’s foundation model technology. The collaboration allows for best-of-breed AI-enabled workflows designed to improve laboratory efficiency, diagnostic quality, and patient outcomes.
The new partnership follows Paige’s recent announcement of a strategic shift to further advancing the role and impact of AI in cancer care, which included transitioning its diagnostic AI applications from being exclusive to the Paige Platform to a standalone solution compatible with other digital pathology platforms.
Through the new collaboration, HALO AP users will be able to execute Paige’s AI applications and view results directly within the HALO AP image management system. Both companies hve also committed to work together commercially to provide best-of-breed solutions for both new and existing customers, as well as engaging in co-development in other areas including pharma services, preclinical, and translational applications.
“We are excited to work with Indica Labs to make Paige’s powerful AI capabilities available to customers through the HALO AP platform,” said Peter Hamilton, GM of Diagnostics at Paige. “We are confident that integrating the technologies that Indica and Paige have developed will provide pathologists with the richest set of capabilities that will drive improvements in cancer diagnostics.”
Steven Hashagen, CEO of Indica Labs said: “This partnership represents a significant step forward in our commitment to delivering innovative solutions that meet the evolving needs of our customers. Paige has been a pioneer in AI for pathology diagnostics, so bringing their tools onto our platform is an exciting opportunity for us and our customers.”
The joint efforts will initially focus on developing integrated solutions catering to clinical diagnostics. Integration roll-out is expected within the next few months, and collaboration efforts for the life science segment are to ensue in parallel.